Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA)
CUSIP: 70261F202
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 24,934,935
- Total 13F shares
- 612,004
- Share change
- +311,660
- Total reported value
- $441,403
- Price per share
- $0.73
- Number of holders
- 18
- Value change
- +$224,539
- Number of buys
- 12
- Number of sells
- 5
Quarterly Holders Quick Answers
What is CUSIP 70261F202?
CUSIP 70261F202 identifies KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 70261F202:
Top shareholders of KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PD Joint Holdings, LLC Series 2016-A |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,608,696
|
$1,124,348 | — | 22 Oct 2022 | |
| Eric Shahinian |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
1,788,415
|
$770,807 | — | 28 Sep 2022 | |
| Orca Capital AG |
13D/G
|
— |
4.9%
|
362,857
|
$613,228 | -$14,002 | 07 May 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
5%
|
317,863
|
$537,188 | $0 | 06 May 2025 | |
| Israel Maxx Abramowitz |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
1,051,575
|
$453,229 | — | 14 Sep 2021 | |
| Dean Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| Eric Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
|
Company |
5%
|
142,082
|
$240,119 | +$14,019 | 31 Mar 2025 | |
| Lawrence Steinman |
13D/G
|
— |
3.1%
|
83,858
|
$141,720 | $0 | 01 Mar 2025 | |
| AdvisorShares Investments LLC |
13F
|
Company |
0.78%
|
193,547
|
$139,605 | — | 30 Jun 2025 | |
| Dr. Yassine Bendiabdallah |
3/4/5
|
Chief Operating Officer, Director |
—
class O/S missing
|
300,000
|
$129,300 | — | 14 Sep 2021 | |
| David Delaney |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
227,521
|
$98,062 | — | 17 Oct 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
62,369
mixed-class rows
|
$34,134 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.17%
|
42,142
|
$30,384 | — | 30 Jun 2025 | |
| Avi Geller |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
54,644
|
$23,552 | — | 19 Aug 2022 | |
| LPL Financial LLC |
13F
|
Company |
0.04%
|
10,000
|
$7,213 | — | 30 Jun 2025 | |
| Kepos Capital LP |
13F
|
Company |
—
class O/S missing
|
334,600
|
$7,000 | — | 30 Jun 2025 | |
| Hurley Capital, LLC |
13F
|
Company |
0.01%
|
3,689
|
$2,661 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.01%
|
1,584
|
$1,142 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,261
|
$910 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
1,051
|
$758 | — | 30 Jun 2025 | |
| Marex Group plc |
13F
|
Company |
—
class O/S missing
|
25,000
|
$388 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
150
|
$108 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
62
|
$44 | — | 30 Jun 2025 | |
| CLEAR STREET LLC |
13F
|
Company |
—
class O/S missing
|
71
|
$2 | — | 30 Jun 2025 | |
| Graeme Martin Currie |
3/4/5
|
Chief Development Officer |
—
class O/S missing
|
5,938
|
— | — | 01 Mar 2024 |
Institutional Holders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA) as of Q3 2025
As of 30 Sep 2025,
Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 per share (KTTA) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
612,004 shares.
The largest 10 holders included
AdvisorShares Investments LLC, CITADEL ADVISORS LLC, VANGUARD GROUP INC, TWO SIGMA INVESTMENTS, LP, XTX Topco Ltd, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, Virtu Financial LLC, JANE STREET GROUP, LLC, and TWO SIGMA SECURITIES, LLC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
10
Q3 2025 holders
18
Holder diff
8
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.